Trials / Completed
CompletedNCT04013048
Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor
A Phase I Mass Balance and Biotransformation Study of [14C]-Fluzoparib in Chinese Patients With Solid Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Study to Evaluate the Mass Balance and Biotransformation of Single Dose \[14C\]-FZPL in Chinese Patients with Solid Tumor
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-Fluzoparib | Patients will receive single dose of orally \[14C\]- Fluzoparib on Day 1. |
Timeline
- Start date
- 2019-07-08
- Primary completion
- 2019-12-24
- Completion
- 2019-12-24
- First posted
- 2019-07-09
- Last updated
- 2020-07-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04013048. Inclusion in this directory is not an endorsement.